Effect of Preoperative Geriatric Nutritional Risk Index on the ED50, ED95, and Sedative Efficacy of Remimazolam Combined with Remifentanil in Elderly Patients Undergoing Painless Gastrointestinal Endoscopy

Start Date08 Jun 2026

Sponsor / Collaborator

Wuxi No. 2 People's Hospital

NCT07651956

/ Not yet recruitingPhase 4IIT

Remimazolam Versus Dexmedetomidine for Procedural Sedation During Neuraxial Anesthesia Placement For Scheduled Cesarean Delivery

Patients presenting for a scheduled cesarean delivery who require a neuraxial anesthetic will be randomized to receive intravenous remimazolam or dexmedetomidine for procedural sedation during the placement of their spinal or epidural anesthesia.

Start Date01 Jun 2026

Sponsor / Collaborator

Icahn School of Medicine at Mount Sinai

100 Clinical Results associated with Remimazolam Tosylate

100 Translational Medicine associated with Remimazolam Tosylate

100 Patents (Medical) associated with Remimazolam Tosylate

1,261

Literatures (Medical) associated with Remimazolam Tosylate

31 Dec 2026·ANNALS OF MEDICINE

Effects of nine sedative-analgesic combinations on fatigue after gastrointestinal endoscopy: a randomized controlled 3 × 3 factorial trial protocol

Article

Author: Huang, Lei ; Kuai, Ling-yu ; Liu, Lin-lin ; Gui, Wen-hu ; Lv, Jun ; Peng, Ke ; Ji, Fu-hai ; Xu, Li-na

INTRODUCTION:

Post-procedural fatigue is common after sedated gastrointestinal endoscopy and prolongs recovery. We describe a protocol for a prospective, single-center, randomized, controlled, 3 × 3 factorial trial to evaluate the effects of different sedative-analgesic combinations on patient-reported fatigue after gastrointestinal endoscopy.

PATIENTS AND METHODS:

Three hundred and fifteen patients (aged ≥ 45 years, ASA physical status I or II) presenting for gastrointestinal endoscopy with planned intravenous sedation will be randomly allocated (1:1:1:1:1:1:1:1:1; block sizes 9 and 18) to one of nine equip-sized groups generated by the factorial combination of three sedatives (propofol, ciprofol, remimazolam) with three adjuvant analgesics (sufentanil, esketamine, lidocaine). Sedation will be titrated to Modified Observer's Assessment of Alertness/Sedation scores of 1-2. The primary outcome is the Christensen Fatigue Scale score (range 1-10; higher = worse) 30 min after the procedure. The secondary outcome is the composite incidence of intra-procedural hypotension (mean arterial pressure < 65 mmHg) and hypoxemia (SpO₂ < 90% for ≥ 10 s). Primary analysis will employ two-way factorial ANOVA to test the main effects of sedatives and analgesics on the 30-min fatigue score, with an exploratory interaction analysis.

DISCUSSION:

The results of this trial will provide high-resolution evidence on which sedative or analgesic agent most effectively mitigates early post-endoscopy fatigue, thereby informing patient-centered sedation choices and enhancing recovery.

TRIAL REGISTRATION:

Chinese Clinical Trial Registry (ChiCTR2500112657; registered on November 18, 2025).

01 Dec 2026·JOURNAL OF MOLECULAR MEDICINE-JMM

The role and mechanism of TNFRSF21 in promoting necroptosis of vascular endothelial cells and inducing vascular leakage in sepsis

Article

Author: She, Han ; Wang, Juntao ; Zhang, Yuxi ; Li, Weichao ; Wang, Xiaoyan ; Wu, Yujia ; Bao, Daiqin ; Yu, Cong ; Shi, Caifeng ; Zhang, Bindan ; Pei, Haoyu ; Mao, Qingxiang

Vascular leakage in sepsis is critical factors in improving the prognosis of septic patients, with limited treatment options targeting underlying molecular mechanisms. Necroptosis is a form of cell death centered around the RIPK1/RIPK3/MLKL pathway, combining both programmed and inflammatory characteristics. However, its role and mechanism in sepsis-induced vascular leakage remain unclear. In vivo and in vitro, CLP and LPS were used to simulate sepsis model. It was found that the expression levels of RIPK1/RIPK3/p-MLKL in septic VECs were significantly increased, and necroptosis inhibitors significantly improved septic vascular leakage. Transcriptomic and Western blot results suggested that TNFRSF21 plays a key role in necroptosis. shTNFRSF21 inhibited the formation of necrosome (RIPK3/p-MLKL) in septic VECs, improved vascular leakage in septic rats, and prolonged their survival time. The compound Phen-DC3 of inhibiting TNFRSF21 and the anesthetic remimazolam, both downregulated TNFRSF21, thereby improving septic vascular leakage. Our results suggest that TNFRSF21-regulated necroptosis plays an important role in septic vascular leakage, and targeting TNFRSF21 inhibition may be a potential therapeutic strategy for septic vascular leakage. KEY MESSAGES: Necroptosis plays a crucial role in sepsis-induced vascular leakage. TNFRSF21 promotes necrosome formation by upregulating RIPK3/p-MLKL, leading to endothelial cell death and disruption of the vascular barrier. The TNFRSF21 inhibitor Phen-DC3 was identified as a compound that improves sepsis-induced vascular leakage, providing a potential new therapeutic strategy for sepsis treatment. The anesthetic remimazolam inhibits TNFRSF21, improving sepsis-induced vascular leakage, offering experimental evidence for the repurposing of existing drugs like remimazolam in the treatment of sepsis.

01 Aug 2026·EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES

Modulation of remimazolam placental transfer via OATP2B1 by rosuvastatin in an in vitro 3D placental barrier model

Article

Author: Toda, Takaki ; Chaki, Tomohiro ; Hirahata, Tomoki ; Yamakage, Michiaki ; Sato, Satoshi ; Kobayashi, Masaki ; Aoyama, Tsuyoshi ; Narumi, Katsuya

Fetal exposure to anesthetics via the placenta during the perinatal period may adversely affect central nervous system development. Organic anion-transporting polypeptide 2B1 (OATP2B1) functions as an active transport carrier across the blood-placental barrier and can be modulated by interactions with rosuvastatin (RSV). This study hypothesized that drug interactions could alter OATP2B1-mediated transport of remimazolam (RMZ), thereby modulating its placental permeability. First, an in vitro 3D blood-placental barrier model was used to assess the permeability of RMZ with a single administration (100 nM RMZ) and co-administration with RSV (0.1, 1, and 10 nM). The apparent permeability coefficient (P_app) of RMZ in the 100 nM RMZ-alone group was significantly lower values at 3 and 4 h than at 2 h (p = 0.047 and p < 0.001, respectively), whereas at 3-4 h post-dose, P_app values were significantly decreased by 15-71% in the groups treated with 1 nM or 10 nM RSV in combination, compared to the RMZ alone group. Next, intracellular uptake assays using OATP2B1-overexpressing human embryonic kidney 293 cells (HEK293) confirmed carrier-mediated transport of RMZ. Uptake was time-dependent, markedly higher than in non-expressing cells, and decreased by 57.6-61.1% in the presence of RSV. These findings demonstrate that RMZ is transported via OATP2B1 through a non-high-affinity binding site and that placental transfer of RMZ can be modulated by drug interactions that alter OATP2B1 function. Considering the differences in OATP2B1 localization between in vivo and in vitro conditions, modification of OATP2B1 transport function by RSV may potentially contribute to increased fetal exposure to RMZ at the blood-placental barrier.

News (Medical) associated with Remimazolam Tosylate

01 Mar 2023

·www.biospace.com

Tachyon Announces Financing and Start of Clinical Study of First-in-Class KDM4 Inhibitor for Advanced Cancers

- First patient enrolled in Phase 1 clinical study of TACH101, a small molecule, KDM4 histone demethylase inhibitor, in patients with advanced or metastatic solid tumors - Tachyon also announces the appointment of Jeff Stafford, Ph.D., to the Company’s Board of Directors SAN FRANCISCO & HOUSTON--(BUSINESS WIRE)-- Tachyon Therapeutics, Inc. ("Tachyon" or "the Company"), a private, clinical-stage biotechnology company developing transformative cancer therapies against novel targets today announced the closing of a financing that brings the Company’s total equity financing raises to $11.6 million and, together with a recently announced CIRM grant of $7.1 million, brings total funding in the Company to $18.7 million since the Company started operations in 2020. The round includes new investors, Veblen Ventures, Khosla Ventures, and Red Tree Venture Capital, and existing investors, demonstrating their continued commitment to supporting Tachyon's potential. Proceeds from the financing are being used to run the Phase 1 clinical study in advanced solid tumors for TACH101, a first-in-class, small molecule, KDM4 histone demethylase inhibitor, as well as to advance the Company’s pipeline of emerging oncology drug candidates targeting previously unexplored mechanisms of tumorigenesis. “The Tachyon team are enabling new frontiers in targeted oncology by developing cancer therapies that address fundamental drivers of tumorigenesis,” commented Heath Lukatch, Ph.D., Managing Director of Red Tree Venture Capital. “We look forward to supporting the team as they work towards transforming the treatment paradigms for advanced and metastatic solid tumors.” “This new capital, from a committed and distinguished investor syndicate that includes new and existing investors as well as the grant from CIRM, highlights the progress we’ve made to bring our lead program into the clinic,” said Frank Perabo, M.D. Ph.D., Chief Executive Officer of Tachyon. Founded on the scientific work of Drs. Stephen Quake and Michael Clarke at Stanford University, Tachyon Therapeutics is developing novel, first-in-class therapeutics that target pathways to fight cancer at its core tumorigenic mechanisms. In November 2019, Tachyon received an exclusive license to research, develop, and commercialize products for small molecule inhibitors of KDM4 including TACH101 (formerly QC8222) from Celgene Quanticel Research, Inc, now Bristol Myers Squibb, Summit, NJ. The Company recently received clearance of the Company’s Investigational New Drug (IND) application for TACH101 and enrolled its first patient in a Phase 1 clinical study in patients with advanced or metastatic solid tumors (ClinicalTrials.gov Identifier NCT05076552). “The start of our first clinical trial for TACH101, our lead program, is a significant milestone for the company as we strive to bring promising new therapeutics to patients who are fighting advanced cancers,” continued Dr. Perabo. “We are also pleased to welcome to our Board of Directors, Dr. Jeff Stafford, who has decades of experience in developing innovative small molecule therapeutics against novel cancer targets and led the initial discovery and development of our novel KDM4-inhibitor, TACH101.” Dr. Stafford is the President and CEO of 858 Therapeutics. Prior to this, he was the founding CSO of Quanticel Pharmaceuticals (acquired by Celgene), where his team discovered TACH101 from a single cell genomics platform for precision targeting of cancer stem cells. Dr. Stafford has also held senior scientific and management positions at Takeda and GlaxoSmithKline and was the founding CEO of Jecure. Dr. Stafford’s discovery teams have been responsible for the discovery of three FDA-approved drugs – Votrient™ (pazopanib), Nesina™ (alogliptin), and Byfavo™ (remimazolam) – and several others currently in clinical trials. About Tachyon Therapeutics Inc. Tachyon Therapeutics, Inc. develops first-in-class therapeutics against novel targets from previously unexplored cancer dysregulation pathways to propel new options for the treatment of advanced cancers. Tachyon operates with a dedicated internal core development team and a virtual external network of expertise to achieve one goal – advance our programs with speed, innovation, quality and scientific integrity. For more information, please visit .

Phase 1Executive ChangeIND

08 Nov 2022

·www.prnewswire.com

Extremely Robust COVID-19 Clinical Trial Pipeline With 420+ Key Companies Expected to Change the Pace of the COVID-19 Treatment

COVID-19 clinical trial pipeline constitutes 420+ key companies continuously working towards developing 520+ COVID-19 vaccines and drugs, analyzes DelveInsight LAS VEGAS, Nov. 8, 2022 /PRNewswire/ -- DelveInsight's ' COVID-19 Competitive Landscape – 2022 ' report provides comprehensive global coverage of available, marketed, and pipeline COVID-19 vaccines in various stages of clinical development, major pharmaceutical companies are working to advance the pipeline space and future growth potential of the COVID-19 competitive domain. Key Takeaways from the COVID-19 Pipeline Report Over 420+ COVID-19 companies are evaluating 520+ COVID-19 pipeline therapies in various stages of development, and their anticipated acceptance in the COVID-19 market would significantly increase market revenue. Leading COVID-19 companies such as Westvac Biopharma, Xenothera, Windtree Therapeutics, Vir Biotechnology, ViiV Healthcare, Verastem, VBL Therapeutics, Vasomune Therapeutics, Inc., Valneva, Uni-Pharma Kleon Tsetis Pharmaceutical Laboratories, UNION Therapeutics, Trustem, Toscana Life Sciences, Throne Biotechnologies, Thirty respiratory Limited, Theravance Biopharma, TC BioPharm, Syntax for Science, S.L, SyneuRx, Swedish Orphan Biovitrum, Swedish Herbal Institute AB, Stemedica Cell Technologies, Staidson (Beijing) Biopharmaceuticals Co., Ltd, Sound Pharmaceuticals, Sorrento Therapeutics, SolAeroMed, SK Bioscience, Sinovac Biotech Co., Ltd, Sinocelltech, Shenzhen Kangtai Biological Products Co., Ltd., Shaperon, Senhwa Biosciences, Inc., Selva Therapeutics, Archivel Farma, R-Pharm, Rohto Pharmaceutical, Revimmune, Resverlogix Corporation, Restorbio, Resolve Therapeutics, Renibus Therapeutics, ReiThera, Regeneron Pharmaceuticals, RedHill Biopharma, Red de Terapia Celular, Reata Pharmaceuticals, Inc., Qurient Co, Quercis Pharma, PureTech, Pulmotect, PTC Therapeutics, Pluristem Ltd., Pliant Therapeutics, Pharming Technologies B.V., Pharmenterprises, Pharmamel S.L., Pharma Holdings, Pharco Pharmaceuticals, Pfizer, Petrovax, Paion UK Ltd., Ashvattha Therapeutics, Inc. (Orpheris), OPKO Health, Oncotelic Inc., National Resilience, Inc. (Ology Bioservices), Olatec Therapeutics LLC, Novavax, Novartis Pharmaceuticals, Notitia Biotechnologies Company, Noorik Biopharmaceuticals, Nobelpharma, Moderna, Moderna, MetrioPharm, Merck Sharp & Dohme Corp., Merck KGaA, Medicago Inc., Mallinckrodt, Mabwell (Shanghai) Bioscience Co., Ltd., Lifefactors Zona Franca, Leading BioSciences, Kiniksa Pharmaceuticals, Ltd., 3M, 4D Pharma, AbbVie, Apotex, AgelessRx, AgenTus Therapeutics, AiCuris, AlloVir, Apeiron Biologics, Bausch Health Americas, BeiGene, Biotest, Bio-Thera Solutions, Cadila Healthcare Limited, Cellenkos, Cellularity Incorporated, Chiesi Farmaceutici S.p.A., Clene Nanomedicine, Codagenix, Debiopharm, Direct Biologics, Eiger BioPharmaceuticals, Emergent Biosolutions, Enlivex Therapeutics, Evergreen Therapeutics, Faron Pharmaceuticals, Frontier Biotechnologies, FSD Pharma, Genentech, Inc., Globavir Biosciences, Grand Medical, Grifols Therapeutics LLC, Inotrem, Ionis Pharmaceuticals, Jazz Pharmaceuticals, Kamada, Kiadis Pharma, Medicine Invention, MedRegen LLC, Miltenyi Biomedicine, Natureceuticals Sdn Bhd, NeoImmune Tech, Neutrolis, Ology Bioservices, Oncovir, OPKO Health, Organicell Regenerative Medicine, and others are evaluating novel drugs for COVID-19 to improve the treatment landscape. Key COVID-19 pipeline therapies in various stages of development include XAV-19, Sinapultide, VIR-7831, Maraviroc, Duvelisib, VB 201, AV-001, VLA2001, T3 solution for injection, UNIKINON, UNI911, Umbilical cord derived mesenchymal stem cells, MAD0004J08, Stem Cell Educator therapy, RESP301, TD-0903, TCB008, Bemiparin, Pentarlandir™ UPPTA, Emapalumab, Kan Jang capsules, hMSC, BDB-001, Ebselen, COVI-DROPS| Placebo, STI-5656, COVI-AMG, PSC-04, S-1226, GBP510, SARS-COV-2 inactivated vaccine, SCTA01, SARS-CoV-2 Vaccine (Vero Cells), Inactivated, NuSepin, Silmitasertib, SLV213, RUTI® vaccine, Olokizumab + RPH-104, Mesenchymal stem cell (ADR-001), CYT107, Apabetalone, RTB101, RSLV-132, RBT-9, GRAd-COV2, REGN-COV2 Antibody Cocktail, ABC 294640, Upamostat, Mesenchymal Stromal Cells, Bardoxolone methyl, Telacebec, IQC-950AN, LYT-100, PUL-042, PTC-299, PLX-PAD, PLN-74809, Conestat alfa, Treamid, Melatonin, LTX-109, Selenium, Ramipril, PF-06650833, Polyoxidonium, Remimazolam, OP-101, Rayaldee, OT-101, ADM03820, OLT 1177, NVXCoV 2373, DFV890, Crizanlizumab, MAS-825, NBT-NM108, Ambrisentan, Sargramostim, Gam-COVID-Vac, mRNA-1283, mRNA-1273, MP1032, Molnupiravir, M5049, Covifenz, INOmax, MW33, COVID-19 convalescent plasma, LB1148, Mavrilimumab, and others. In October 2022, eFFECTOR Therapeutics announced the completion of enrollment for the second cohort of a three-cohort Phase Ib clinical trial of zotatifin in non-hospitalized adults with confirmed COVID-19 infection. In October 2022, Pfizer/BioNTech and Moderna's bivalent COVID-19 booster vaccines targeting the BA.4 and BA.5 subvariants of Omicron have been approved for use in children and adolescents in the United States. In October 2022, an intranasal formulation of AstraZeneca's widely used COVID-19 vaccine, Vaxzevria, failed at the first hurdle, with results from a phase I trial revealing that it was unable to stimulate a strong immune response to the virus. In September 2022, Bharat Biotech's Covid-19 vaccine candidate codenamed BBV154, which has now been rechristened iNCOVACC became the world's first intranasal Covid-19 vaccine to be granted emergency use authorization (EUA) after the Indian drug regulator approved it for a two-dose primary immunization of those aged 18 years and above. COVID-19 intranasal vaccine (BBV154) has proven to be safe, well-tolerated, and immunogenic in subjects in controlled clinical trials phase III In July 2022, Revive Therapeutics Ltd. is pleased to provide an update on the Company's U.S. Food & Drug Administration ("FDA") Phase III clinical trial (the "Study") (NCT04504734) to evaluate the safety and efficacy of Bucillamine, an oral drug with anti-inflammatory and antiviral properties, in patients with mild to moderate COVID-19. The Company had unblinded the pre-dose selection data (the "Data") to potentially support the amended Study protocol with the new primary efficacy endpoints. The assigned unblinded statistician team is currently analyzing the Data, and the Company aims to submit the amended Study protocol to the FDA shortly thereafter. The proposed new primary efficacy endpoints may include the rate of sustained clinical resolution of symptoms of COVID-19, which addresses the shift in COVID-19 clinical outcomes observed over the course of the pandemic, and, therefore, to have more meaningful study endpoints for the FDA to consider for potential Emergency Use Authorization In April 2022, Direct Biologics, FDA approved the company to proceed with its Phase III clinical trial using its investigational EV drug, ExoFlo, to treat Acute Respiratory Distress Syndrome (ARDS) due to Covid-19. Direct Biologics is the first and only EV Company to receive FDA Phase III approval for an Investigational New Drug (IND) indication to date In April 2022, Direct Biologics announced that the US Food and Drug Administration (FDA) had awarded their EV drug product ExoFlo with a Regenerative Medicine Advanced Therapy (RMAT) designation for the treatment of Acute Respiratory Distress Syndrome (ARDS) associated with COVID-19. In March 2022, Akston Biosciences Corp and Biolexis, a division of Stelis Biopharma Ltd., entered into a licensing, manufacturing, and commercialization agreement for Akston's AKS-452, a protein subunit COVID-19 vaccine. Biolexis gained the right to manufacture and commercialize AKS-452 (branded as AmbiVax-CTM) in India and over 130 countries in Asia, Latin America, and Africa, largely covering the low-and-middle-income countries (LMICs). Biolexis will also leverage the capabilities of Strides Group for launching this vaccine across regions where the group has a deep market presence, and established relationships Request a sample and discover the recent advances in COVID-19 treatment @ COVID-19 Competitive Landscape Report COVID-19 Overview Coronavirus disease (COVID-19) is an infectious disease caused by the most recently discovered coronavirus, SARS coronavirus 2. (SARS-CoV-2). COVID-19 causes a respiratory illness similar to the flu. The COVID-19 symptoms include cough, fever, and difficulty breathing. The majority of people infected with the COVID-19 virus will experience mild to moderate respiratory illness and will recover without the need for special care. People over the age of 65 and those with underlying medical conditions such as cardiovascular disease, diabetes, chronic respiratory disease, and cancer are more likely to develop serious illnesses. When an infected person coughs or sneezes, the COVID-19 virus is primarily transmitted through saliva or nasal discharge droplets. Discover more about COVID-19 testing @ New Treatment for COVID-19 COVID-19 Pipeline Analysis: Drug Profile Sargramostim: Nobelpharma Nobelpharma's drug Sargramostim is a synthetic version of a natural substance produced in the body. It is used to boost the body's production of white blood cells. Sargramostim is given to patients with decreased ability to produce white blood cells. It is also used in some medical procedures (for example, bone marrow/stem cell transplants). It is a supportive medication but does not aid cancer treatment. The product is currently in Phase II/III development for the treatment of COVID-19. Sotrovimab: Vir Biotechnology Vir Biotechnology's Sotrovimab is a monoclonal antibody that neutralizes SARS-CoV-2. The antibody binds to an epitope on SARS-CoV-2 that is shared with SARS-CoV-1 (the virus that causes SARS), indicating that the epitope is highly conserved, which may make resistance development more difficult. Sotrovimab, which incorporates Xencor, Inc.'s XtendTM technology, has also been designed to achieve high concentrations in the lungs for optimal penetration into SARS-CoV-2-affected airway tissues and to have an extended half-life. Discover more about the list of FDA-approved drugs for COVID-19 @ Antiviral Drugs for COVID-19 Treatment A snapshot of the COVID-19 Pipeline Drugs mentioned in the report: Learn more about the emerging COVID-19 pipeline therapies @ COVID-19 Clinical Trials Scope of the COVID-19 Competitive Landscape Report Coverage: Global Key COVID-19 Companies: Westvac Biopharma, Xenothera, Windtree Therapeutics, Vir Biotechnology, ViiV Healthcare, Verastem, VBL Therapeutics, Vasomune Therapeutics, Inc., Valneva, Uni-Pharma Kleon Tsetis Pharmaceutical Laboratories, UNION Therapeutics, Trustem, Toscana Life Sciences, Throne Biotechnologies, Thirty respiratory Limited, Theravance Biopharma, TC BioPharm, Syntax for Science, S.L, SyneuRx, Swedish Orphan Biovitrum, Swedish Herbal Institute AB, Stemedica Cell Technologies, Staidson (Beijing) Biopharmaceuticals Co., Ltd, Sound Pharmaceuticals, Sorrento Therapeutics, SolAeroMed, SK Bioscience, Sinovac Biotech Co., Ltd, Sinocelltech, Shenzhen Kangtai Biological Products Co., Ltd., Shaperon, Senhwa Biosciences, Inc., Selva Therapeutics, Archivel Farma, R-Pharm, Rohto Pharmaceutical, Revimmune, Resverlogix Corporation, Restorbio, Resolve Therapeutics, Renibus Therapeutics, ReiThera, Regeneron Pharmaceuticals, RedHill Biopharma, Red de Terapia Celular, Reata Pharmaceuticals, Inc., Qurient Co, Quercis Pharma, PureTech, Pulmotect, PTC Therapeutics, Pluristem Ltd., Pliant Therapeutics, Pharming Technologies B.V., Pharmenterprises, Pharmamel S.L., Pharma Holdings, Pharco Pharmaceuticals, Pfizer, Petrovax, Paion UK Ltd., Ashvattha Therapeutics, Inc. (Orpheris), OPKO Health, Oncotelic Inc., National Resilience, Inc. (Ology Bioservices), Olatec Therapeutics LLC, Novavax, Novartis Pharmaceuticals, Notitia Biotechnologies Company, Noorik Biopharmaceuticals, Nobelpharma, Moderna, Moderna, MetrioPharm, Merck Sharp & Dohme Corp., Merck KGaA, Medicago Inc., Mallinckrodt, Mabwell (Shanghai) Bioscience Co., Ltd., Lifefactors Zona Franca, Leading BioSciences, Kiniksa Pharmaceuticals, Ltd., 3M, 4D Pharma, AbbVie, Apotex, AgelessRx, AgenTus Therapeutics, AiCuris, AlloVir, Apeiron Biologics, Bausch Health Americas, BeiGene, Biotest, Bio-Thera Solutions, Cadila Healthcare Limited, Cellenkos, Cellularity Incorporated, Chiesi Farmaceutici S.p.A., Clene Nanomedicine, Codagenix, Debiopharm, Direct Biologics, Eiger BioPharmaceuticals, Emergent Biosolutions, Enlivex Therapeutics, Evergreen Therapeutics, Faron Pharmaceuticals, Frontier Biotechnologies, FSD Pharma, Genentech, Inc., Globavir Biosciences, Grand Medical, Grifols Therapeutics LLC, Inotrem, Ionis Pharmaceuticals, Jazz Pharmaceuticals, Kamada, Kiadis Pharma, Medicine Invention, MedRegen LLC, Miltenyi Biomedicine, Natureceuticals Sdn Bhd, NeoImmune Tech, Neutrolis, Ology Bioservices, Oncovir, OPKO Health, Organicell Regenerative Medicine, and others Key COVID-19 Pipeline Therapies: XAV-19, Sinapultide, VIR-7831, Maraviroc, Duvelisib, VB 201, AV-001, VLA2001, T3 solution for injection, UNIKINON, UNI911, Umbilical cord derived mesenchymal stem cells, MAD0004J08, Stem Cell Educator therapy, RESP301, TD-0903, TCB008, Bemiparin, Pentarlandir™ UPPTA, Emapalumab, Kan Jang capsules, hMSC, BDB-001, Ebselen, COVI-DROPS| Placebo, STI-5656, COVI-AMG, PSC-04, S-1226, GBP510, SARS-COV-2 inactivated vaccine, SCTA01, SARS-CoV-2 Vaccine (Vero Cells), Inactivated, NuSepin, Silmitasertib, SLV213, RUTI® vaccine, Olokizumab + RPH-104, Mesenchymal stem cell (ADR-001), CYT107, Apabetalone, RTB101, RSLV-132, RBT-9, GRAd-COV2, REGN-COV2 Antibody Cocktail, ABC 294640, Upamostat, Mesenchymal Stromal Cells, Bardoxolone methyl, Telacebec, IQC-950AN, LYT-100, PUL-042, PTC-299, PLX-PAD, PLN-74809, Conestat alfa, Treamid, Melatonin, LTX-109, Selenium, Ramipril, PF-06650833, Polyoxidonium, Remimazolam, OP-101, Rayaldee, OT-101, ADM03820, OLT 1177, NVXCoV 2373, DFV890, Crizanlizumab, MAS-825, NBT-NM108, Ambrisentan, Sargramostim, Gam-COVID-Vac, mRNA-1283, mRNA-1273, MP1032, Molnupiravir, M5049, Covifenz, INOmax, MW33, COVID-19 convalescent plasma, LB1148, Mavrilimumab, and others. Dive deep into rich insights for drugs for COVID-19 treatment; visit @ COVID-19 Vaccines Table of Contents For further information on the COVID-19 guidelines, reach out @ COVID-19 Treatment Guidelines Related Reports COVID-19 Pipeline COVID-19 Pipeline Insight – 2022 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key COVID-19 companies, including Chiesi Farmaceutici S.p.A., Clene Nanomedicine, Codagenix, Debiopharm, Direct Biologics, Eiger BioPharmaceuticals, Emergent Biosolutions, Enlivex Therapeutics, Evergreen Therapeutics, Faron Pharmaceuticals, among others. Common Cold Market Common Cold Market Insights, Epidemiology, and Market Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key common cold companies, including Sanotize Research and Development, Orbis Biosciences, Exscientia, EURRUS Biotech, among others. Common Cold Pipeline Common Cold Pipeline Insight – 2022 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key common cold companies, including Sanotize Research and Development, Orbis Biosciences, Exscientia, EURRUS Biotech, among others. Common Cold Epidemiology Common Cold Epidemiology Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted common cold epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan. Acute Respiratory Distress Syndrome Market Acute Respiratory Distress Syndrome Market Insights, Epidemiology, and Market Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key acute respiratory distress syndrome companies, including MediciNova, Edesa Biotech, Light Chain Biosciences, Boehringer Ingelheim, Genentech, among others. Chronic Obstructive Pulmonary Disease Market Chronic Obstructive Pulmonary Disease Market Insights, Epidemiology, and Market Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key chronic obstructive pulmonary disease companies, including United Therapeutics, Verona Pharma PLC, AstraZeneca, Chiesi Farmaceutici S.p.A., GlaxoSmithKline, among others. Other Trending Reports Goitre Market | Thymus Cancer Market | US Healthcare Outlook Report | Venous Stenosis Market | Negative Pressure Wound Therapy Systems Market | Global Kinase Inhibitor in Autoimmune Diseases Market | Metrorrhagia Market | Dysfunctional Uterine Bleeding Market | Hypereosinophilic Syndrome Market | Age-related Vision Dysfunction Market | Dental Lasers Market | CRISPR Therapies Pipeline Insight | Cell And Gene Therapy For Multiple Myeloma Market | Drug Hypersensitivity Market | Dysthymia Market | Persistent Depressive Disorder Market | Cancer Vaccines Market | Weight Loss/Weight Management (Obesity) Market | Food Allergy Market | Obsessive-Compulsive Disorder Market | Tumor Ablation Market | Physiotherapy Equipment Market | Chimeric Antigen Receptor (CAR) T-Cell Therapy Market | Anti-hypertension Market | Radiofrequency Ablation Devices Market | Global Messenger RNA (mRNA)-based Vaccines and Therapeutics Market | Gastro Intestinal Bleeding Market | Trastuzumab Biosimilars Insight | Varicose Veins Market | Germ Cell Tumor Market | Intracardiac Echocardiography Devices Market | India Healthcare Report | Crows Feet Market | Seborrhoeic Dermatitis Market | Injectable Drug Delivery Devices Market | Structural Heart Devices Market | Substance (Drug) Abuse Market | Insulin Glargine Biosimilar Insight Related Healthcare Blogs Increasing COPD Prevalence ARDS Market Outlook Emerging ARDS Therapies About DelveInsight DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. Connect with us at LinkedIn Contact Us Shruti Thakur [email protected] +1(919)321-6187 Logo: SOURCE DelveInsight Business Research, LLP

VaccineGene TherapyAntibodyBiosimilarCell Therapy

100 Deals associated with Remimazolam Tosylate

External Link

KEGG	Wiki	ATC	Drug Bank
-	Remimazolam Tosylate	N05CD14	DB12404

R&D Status

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Anesthesia	China	Jiangsu Hengrui Pharmaceuticals Co., Ltd.	22 Dec 2021
Sedation	China	Jiangsu Hengrui Pharmaceuticals Co., Ltd.	26 Dec 2019

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT06222294 (Pubmed \| Anesthesiology)	Phase 3	Sedation	211	Remimazolam tosylate	pvkmoiwmiw(svdvlexznz) = rddxgxqltw nvmqpavucz (zosaclwyat ) View more	Non-inferior	01 Jul 2026
				Propofol	pvkmoiwmiw(svdvlexznz) = aixywnwnqu nvmqpavucz (zosaclwyat ) View more
NCT05152303 (Pubmed \| J Intensive Med)	Phase 2	Sedation	59	Remimazolam tosylate (low adjustment rate)	tyhfnafyhq(wgdlkpmenz) = gdrhzfymzr omgyzcqdnw (ujilpizaqh, 93.8 - 99.7) View more	Positive	01 Jun 2026
				Remimazolam tosylate (high adjustment rate)	mbimzithrh(gjpvjmnyqd) = vpvmoeshpf prybyulzma (gsnmysgwqx ) View more
NCT06565715 (Pubmed \| BMC Anesthesiol)	Phase 4	-	66	Remimazolam anesthesia	huatkawvcr(ykupgrafhh) = yetdmnlgqx lmxzymwibx (litkhxjuuw, 3.2) View more	Positive	20 Aug 2025
				Propofol anesthesia	huatkawvcr(ykupgrafhh) = hiowncuvor lmxzymwibx (litkhxjuuw, 6.0) View more
NCT06013345 (COOPERATIVE-PFA, Pubmed \| Circulation)	Phase 4	Atrial Fibrillation	127	DAS using intermittent propofol-opioid boluses	ujtgwjaypd(rtbuakobol) = wiixxvedkw hflllnfvsx (zwygspdmaa )	Positive	22 Jul 2025
				continuous remimazolam-ketamine DAS	ujtgwjaypd(rtbuakobol) = eeukwcoxix hflllnfvsx (zwygspdmaa )
NCT06178848 (Pubmed \| Anesth Analg)	Not Applicable	Emergence Delirium	48	Remimazolam-induced anesthesia	uaaobrkggj(gmlqwkdcrf) = thwkscaskh wwykrrheeb (diwqlgazqk, 0.0 - 21.0)	Positive	25 Apr 2025
ChiCTR2300071256 (Pubmed \| BMC Anesthesiol)	Phase 4	Maintenance	122	Remimazolam tosilate	utajinvnvy(afsdmjjvmd) = lepovfotis qqgxwqjgqv (znumntgjjs, 2.6) View more	Positive	06 Jul 2024
				Propofol	utajinvnvy(afsdmjjvmd) = kbnnjawrmr qqgxwqjgqv (znumntgjjs, 4.3) View more
NCT05164146 (Pubmed \| BMC Anesthesiol)	Not Applicable	Hypertension	94	Remimazolam-based TIVA	daknmhxyle(iqkpxaiixp) = tbyzcbnwjc hrkvqrvxyn (agqhmtxmic )	Positive	04 Jun 2024
				Propofol-based TIVA	daknmhxyle(iqkpxaiixp) = bnulkcczio hrkvqrvxyn (agqhmtxmic )
Pubmed \| Br J Anaesth	Not Applicable	Sedation	4,516	Remimazolam + short-acting opioid	oepliqoife(wrpfiotzoo) = nytvcgjsyv zmnkqldtez (tohqbtbfvn, 4 - 13)	Positive	01 Jun 2024
DDW 12024 \| DDW 22024 \| DDW 32024 \| DDW 42024	Not Applicable	-	-	Remimazolam	momugadokn(qzlrixhjfc) = zzruvhahym axkmmkiigx (orqwebiodl ) View more	-	21 May 2024
NCT05053763 (Pubmed)	Not Applicable	-	55	Remimazolam 0.2 mg/kg	tpfczgyega(wkhyamuzxs) = 2 patients developed bradycardia wakfrdbkmc (sgtxetegqh ) View more	Positive	14 May 2024
				Remimazolam 0.300 mg/kg

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis